Bellevue Life Sciences Acquisition - Units (1 Ord, 1 War & 1 Right ) EBIT

Bellevue Life Sciences Acquisition - Units (1 Ord, 1 War & 1 Right ) (BLACU) currently reports a EBIT of $-21M as of June 2026. That compares with $-11M in the prior-year period — down 85.0% year over year. That is above the sector sector average of $-26M. Use the charts on this page to explore Bellevue Life Sciences Acquisition - Units (1 Ord, 1 War & 1 Right )'s EBIT history and peer comparisons.

Bellevue Life Sciences Acquisition - Units (1 Ord, 1 War & 1 Right )'s EBIT decreased from $-11M to $-21M — a 85.0% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Bellevue Life Sciences Acquisition - Units (1 Ord, 1 War & 1 Right )'s EBIT of $-21M is higher than the its sector sector average of $-26M. That is roughly 20.0% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Bellevue Life Sciences Acquisition - Units (1 Ord, 1 War & 1 Right ) reported $-21M in EBIT as of June 2026. That compares with $-11M in the prior-year period — down 85.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-21M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $-26M. From there, open related valuation or income-statement pages for Bellevue Life Sciences Acquisition - Units (1 Ord, 1 War & 1 Right ), and consider following BLACU for alerts when major investors trade the stock.